» Articles » PMID: 25605003

Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism

Overview
Publisher Wiley
Specialty Rheumatology
Date 2015 Jan 22
PMID 25605003
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis. The reduction in cardiovascular risk that is induced by methotrexate (MTX) and anti-tumor necrosis factor α agents in RA is considered secondary to their anti-inflammatory action, but their effects on serum lipoprotein function and foam cell formation are unknown. The reduced capacity of high-density lipoprotein (HDL) to promote cell cholesterol efflux and the increased serum cell cholesterol-loading capacity (CLC) demonstrated in RA may contribute to foam cell development. The aim of this study was to investigate the influence of MTX and adalimumab treatment on serum cholesterol efflux capacity (CEC) and CLC in RA patients and to study the in vitro effects of the two drugs on macrophage cholesterol handling.

Methods: Sera from RA patients treated with MTX (n = 34) or with adalimumab and MTX (n = 22) obtained before treatment, after 6 weeks of treatment, and after 6 months of treatment were analyzed for CEC and CLC by radioisotopic and fluorometric techniques, respectively. The influence of MTX and adalimumab on macrophage cholesterol efflux and uptake was evaluated in vitro using human THP-1-derived macrophages.

Results: MTX treatment was associated with increases in serum HDL, low-density lipoprotein, and total cholesterol levels and with ATP-binding cassette G1-mediated and scavenger receptor class B type I (SR-BI)-mediated increases in CEC; MTX treatment was not associated with modifications in CLC. Adalimumab treatment was associated with increases in serum HDL levels, a transient increase in SR-BI-mediated CEC, a transient decrease in ATP-binding cassette A1-mediated CEC, and a significant reduction in CLC; in addition, adalimumab reduced macrophage cholesterol uptake in vitro.

Conclusion: Antiatherosclerotic activity associated with MTX and adalimumab may be mediated by beneficial and complementary effects on lipoprotein functions and on macrophage cholesterol handling. As a whole, these mechanisms may oppose foam cell formation.

Citing Articles

Changes in serum cholesterol loading capacity are linked to coronary atherosclerosis progression in rheumatoid arthritis.

Karpouzas G, Papotti B, Ormseth S, Palumbo M, Hernandez E, Adorni M RMD Open. 2024; 10(4.

PMID: 39719397 PMC: 11683967. DOI: 10.1136/rmdopen-2024-004991.


Unraveling the Pleiotropic Role of High-Density Lipoproteins (HDLs) in Autoimmune Rheumatic Diseases.

Giacaglia M, Pires V, Santana M, Passarelli M Int J Rheumatol. 2024; 2024:1896817.

PMID: 39574464 PMC: 11581784. DOI: 10.1155/2024/1896817.


The Composition of the HDL Particle and Its Capacity to Remove Cellular Cholesterol Are Associated with a Reduced Risk of Developing Active Inflammatory Rheumatoid Arthritis.

Giacaglia M, Felix V, Santana M, Amendola L, Lerner P, Fernandes S Int J Mol Sci. 2024; 25(20).

PMID: 39456762 PMC: 11507075. DOI: 10.3390/ijms252010980.


Heart Failure in Rheumatoid Arthritis: Clinical Implications.

Zambrano Zambrano A, Del Rio Zanatta H, Gonzalez Espinoza A, Bernal Alferes B, Zambrano Zambrano K, Martinez Salazar J Curr Heart Fail Rep. 2024; 21(6):530-540.

PMID: 39287753 DOI: 10.1007/s11897-024-00682-w.


Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis.

Karpouzas G, Ormseth S, van Riel P, Gonzalez-Gay M, Corrales A, Rantapaa-Dahlqvist S RMD Open. 2024; 10(3).

PMID: 39043615 PMC: 11268070. DOI: 10.1136/rmdopen-2024-004546.